Boehringer Ingelheim
3 articles
Industry NewsBoehringer Ingelheim / Zealand PharmaBioSpace
Boehringer, Zealand's survodutide shows no added heart risk in Phase 3 CV safety trial
- In the Phase 3 SYNCHRONIZE-CVOT trial (5,530 adults with overweight or obesity and elevated cardiovascular risk), survodutide was non-inferior to placebo on major cardiovascular events.
- Results were presented at AHA and published in The Lancet; at 72 weeks it also lowered systolic blood pressure and waist circumference versus placebo.
- GI-related discontinuations ran about 19-21% versus 1.9% on placebo; Zealand attributes this to limited titration flexibility, and analysts flag tolerability as a liability.
- The data support global regulatory filings for obesity.
Clearing the CV safety bar de-risks filing, but survodutide arrives behind semaglutide and tirzepatide with GI discontinuations near 20%, which is hard to defend commercially. Its real differentiation is glucagon-driven liver benefit; the MASH data and any gentler titration results will decide whether it is a contender or a follower.
Industry NewsBoehringer Ingelheim / Sino Biopharmaceutical (SBP Group)BioSpace
Boehringer Takes Options on Six Preclinical Oncology Programs from Sino Biopharm's Subsidiaries, Worth Up to $7B
- Boehringer Ingelheim and SBP Group signed a second oncology collaboration after their 2024 deal: six preclinical antibody–drug conjugate and T-cell engager programs.
- Boehringer pays $358 million upfront and near-term; SBP is eligible for up to $7 billion in option-exercise and milestone payments plus tiered royalties.
- Five programs come from LaNova, one from Beijing Tide. SBP runs early development, and Boehringer can opt in per asset after undisclosed clinical milestones; four options give rights excluding some Asian countries, two give global rights.
The structure is the story: Boehringer pays to watch SBP fund the risky preclinical-to-clinic step, then chooses asset by asset, so most of the $7 billion is only paid if programs survive. It is the same China-sourcing playbook Pfizer, Merck and others use, with a Shanghai R&D site added a month ago to evaluate assets in-house. Six ADC/TCE shots in one deal also bets that Chinese bispecific and conjugate engineering stays ahead of Western platforms.
Industry NewsBoehringer Ingelheim / Zealand PharmaFierce Biotech
Survodutide's second underwhelming phase 3 read-out knocks Zealand's shares
- Boehringer Ingelheim and Zealand's survodutide produced weight loss of up to roughly 13% in people with diabetes in phase 3.
- Zealand's shares fell sharply after the data, which landed a day after Lilly's eloralintide–tirzepatide combination read-out.
- Gastrointestinal side effects drove about 18% of treated patients to stop, keeping tolerability in question.
- It is the second recent disappointment for the compound after earlier SYNCHRONIZE-1 data.
The efficacy sits between semaglutide 2.4 mg and top-dose tirzepatide, but timing is brutal: Lilly's amylin combination landed 24 hours earlier at a far higher weight-loss level. With roughly one in five patients dropping out on GI effects, survodutide's remaining angle is MASH, where glucagon activity is the differentiator, not raw weight loss. Expect investors to price Zealand on that liver story and on how Boehringer positions dosing and titration.